Physician profile
Ryan Drumright
NPI 1689938060
$3,357.03
in general payments reported to CMS, 2019-2025
27 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $225 · 2021: $467 · 2022: $259 · 2023: $331 · 2024: $722 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $813.80 | 2019-2025 | Argos, Clareon, Rocklatan |
| Abbvie INC. | $501.86 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $275.15 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $181.55 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $168.71 | 2019-2025 | |
| Biotissue Holdings INC. | $160.11 | 2024-2025 | |
| Oyster Point Pharma, INC. | $148.40 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $146.21 | 2019-2021 | |
| Dompe US, INC. | $139.67 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $139.37 | 2024-2025 | Vevye |
| Ivantis, INC | $118.36 | 2021 | |
| Carl Zeiss Meditec, INC. | $79.19 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $63.18 | 2021 | |
| Thea Pharma INC. | $60.62 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $60.31 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $54.39 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $43.06 | 2022 | |
| Kala Pharmaceuticals, INC. | $32.86 | 2020 | |
| Allergan, INC. | $27.29 | 2020-2022 | |
| Glaukos Corporation | $24.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.36 | 2020 | |
| Horizon Therapeutics Plc | $20.12 | 2021 | |
| Ocular Therapeutix, INC. | $17.73 | 2023 | Dextenza |
| Omeros Corporation | $16.85 | 2020 | |
| Amgen INC. | $14.54 | 2024 | Tepezza |
| Hologic Sales and Service, LLC | $13.34 | 2021 | |
| Halozyme INC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Drumright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.